Article Text

Download PDFPDF
Correspondence response
Response to: ‘Drug survival on TNF inhibitors: 2003–2004 data from Italian National Register (GISEA Register)’ by Iannone et al
  1. Martin Neovius,
  2. Johan Askling
  1. Karolinska Institutet, Clinical Epidemiology Unit (T2), Stockholm, Sweden
  1. Correspondence to Dr Martin Neovius, Karolinska Institutet, Clinical Epidemiology Unit (T2), Stockholm 17176, Sweden; martin.neovius{at}

Statistics from

We thank Iannone et al for their comment1 on our recent study on drug survival on etanercept, infliximab and adalimumab in patients with rheumatoid arthritis (RA).2 They noted similarities between our findings and their previously published data3 on 853 Italian patients starting tumour necrosis factor (TNF) inhibitor treatment in 2003–2004 in terms of best drug survival on etanercept, similar 4- versus 5-year drug survival for etanercept and infliximab, and some shared findings regarding predictors. We agree that there are several similarities, but also differences. We also apologise for not including their study in our non-exhaustive review in the appendix, and not citing their study together with the study by Kievit et al.4

Specifically, we …

View Full Text


  • Competing interests None.

  • Funding The original study was partly funded by the Swedish Foundation for Strategic Research (SSF), and by Astra Zeneca via the public private partnership COMBINE. Neither SSF nor Astra Zeneca had any influence on the study design, data acquisition, analysis, interpretation of the results, or writing of the manuscript. Astra Zeneca representatives were allowed to comment upon the findings prior to submission although all final decisions resided with the investigators.

  • Data sharing No additional data available.

  • Ethics approval Regional Ethics Committee at Karolinska institutet.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles